Growing community of inventors

Orbe, Switzerland

Pascal Benderitter

Average Co-Inventor Count = 6.54

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 21

Pascal BenderitterAndreas Muhs (2 patents)Pascal BenderitterWolfgang Froestl (2 patents)Pascal BenderitterHeiko Kroth (2 patents)Pascal BenderitterNampally Sreenivasachary (2 patents)Pascal BenderitterCotinica Hamel (2 patents)Pascal BenderitterEddy Jean Edgard Freyne (1 patent)Pascal BenderitterValerio Berdini (1 patent)Pascal BenderitterGordon Saxty (1 patent)Pascal BenderitterWerner Constant Johan Embrechts (1 patent)Pascal BenderitterBerthold Wroblowski (1 patent)Pascal BenderitterAlexandra Papanikos (1 patent)Pascal BenderitterRhalid Akkari (1 patent)Pascal BenderitterWerner Constant Johan Embrechts (0 patent)Pascal BenderitterPascal Benderitter (3 patents)Andreas MuhsAndreas Muhs (34 patents)Wolfgang FroestlWolfgang Froestl (11 patents)Heiko KrothHeiko Kroth (9 patents)Nampally SreenivasacharyNampally Sreenivasachary (3 patents)Cotinica HamelCotinica Hamel (2 patents)Eddy Jean Edgard FreyneEddy Jean Edgard Freyne (46 patents)Valerio BerdiniValerio Berdini (43 patents)Gordon SaxtyGordon Saxty (41 patents)Werner Constant Johan EmbrechtsWerner Constant Johan Embrechts (32 patents)Berthold WroblowskiBerthold Wroblowski (11 patents)Alexandra PapanikosAlexandra Papanikos (9 patents)Rhalid AkkariRhalid Akkari (5 patents)Werner Constant Johan EmbrechtsWerner Constant Johan Embrechts (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Ac Immune Sa (2 from 63 patents)

2. Astex Therapeutics Limited (1 from 123 patents)


3 patents:

1. 10500207 - Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

2. 9221812 - Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

3. 8481531 - Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/9/2026
Loading…